Resveratrol Attenuates IL‑33‑induced Mast Cell Inflammation Associated with Inhibition of NF‑κB Activation and the P38 Signaling Pathway

Yundan Xu,Qiang Liu,Xiaohong Guo,Lei Xiang,Gang Zhao
DOI: https://doi.org/10.3892/mmr.2020.10952
IF: 3.423
2020-01-01
Molecular Medicine Reports
Abstract:Resveratrol (RSV), a natural polyphenol found in grapes and other herbal plants, has been reported to possess anti-inflammatory, anti-oxidative and anti-proliferative activities. The aim of the present study was to investigate the effect of RSV on interleukin (IL)-33-induced inflammatory responses in mast cells and identify the underlying molecular mechanisms. Rat basophilic leukemia (RBL-2H3) cells were stimulated with IL-33 in the presence or absence of RSV. MTT, ELISA, reverse transcription-quantitative PCR and western blot analyses were then performed in order to assess cytotoxicity, inflammatory cytokine production, suppression of tumorigenicity 2 receptor expression, protein expression involved in mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-kappa B signaling, respectively. Finally, rats were used to determine the biological effect of RSV in vivo. The results revealed that RSV inhibited cell viability and increased cytotoxicity in a dose-dependent manner. Medium concentration of RSV (10 mu M) treatment attenuated inflammatory cytokine production, such as IL-6, IL-13, tumor necrosis factor-alpha and monocyte chemotactic protein-1, and curbed IL-33-induced enhancement of immunoglobulin E-mediated responses in RBL-2H3 cells, which were associated with the suppression of NF-kappa B-mediated transcription and inhibition of P38 phosphorylation in response to IL-33 stimulation, but not extracellular signal regulated kinase or JNK. Notably, RSV application also decreased the levels of inflammatory cytokines in rats induced by IL-33 injection, which was similar to the anti-inflammatory effect in vitro. The data from the present study demonstrated that RSV played a regulatory role in antagonizing the effects of IL-33 on mast cells both in vitro and in vivo, suggesting that it has therapeutic potential in IL-33-mediated inflammatory diseases that are associated with mast cells.
What problem does this paper attempt to address?